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Kcne2 deletion causes early-onset 
nonalcoholic fatty liver disease via 
iron deficiency anemia
Soo Min Lee1, Dara Nguyen1, Marie Anand1, Ritu Kant1, Clemens Köhncke2, Ulrike Lisewski2, 
Torsten K. Roepke2,3, Zhaoyang Hu4 & Geoffrey W. Abbott1
Nonalcoholic fatty liver disease (NAFLD) is an increasing health problem worldwide, with genetic, 
epigenetic, and environmental components. Here, we describe the first example of NAFLD caused 
by genetic disruption of a mammalian potassium channel subunit. Mice with germline deletion of 
the KCNE2 potassium channel β subunit exhibited NAFLD as early as postnatal day 7. Using mouse 
genetics, histology, liver damage assays and transcriptomics we discovered that iron deficiency arising 
from KCNE2-dependent achlorhydria is a major factor in early-onset NAFLD in Kcne2─/─ mice, while two 
other KCNE2-dependent defects did not initiate NAFLD. The findings uncover a novel genetic basis for 
NAFLD and an unexpected potential factor in human KCNE2-associated cardiovascular pathologies, 
including atherosclerosis.
NAFLD is the predominant liver disorder in many developed and developing countries, affecting as much 
as a third of the United States population1. Characterized by abnormally high hepatic lipid accumulation, 
NAFLD is of particular importance because it can progress to more dangerous disorders including nonalco-
holic steatohepatitis (NASH) and potentially fatal liver cirrhosis2. NAFLD is commonly associated with met-
abolic syndrome, hypercholesterolemia and hypertriglyceridemia, and is often observed in obese or diabetic 
individuals, those with poor eating habits, or people who have experienced rapid weight loss. In addition, 
people without these risk factors can also develop NAFLD, and the incidence and severity of the disease is 
influenced by a variety of genetic and epigenetic factors in addition to lifestyle and other environmental 
influences1.
Sequence variants in six genes have been both linked to human NAFLD and independently validated (for 
review see1). The I148M variant in PNPLA3, which encodes patatin-like phospholipase domain-containing pro-
tein 3, is the major recognized genetic basis for NAFLD in human populations3. When the PNPLA3 I148M 
human NAFLD-associated polymorphism (rs738409) is overexpressed in mice, it results in triacyglycerol (TAG) 
accumulation. Similar results are obtained by targeted hepatic overexpression of wild-type PNPLA3 in mice, 
via increased TAG and fatty acid synthesis and impaired hydrolysis of TAG; a relative depletion of long-chain 
polyunsaturated forms of TAG was also observed4,5. The other five genes are GCKR (which regulates glucoki-
nase activity and hepatic glucose intake)6; PEMT, a catalyst for phosphatidylcholine synthesis7; SOD2 (which 
clears mitochondrial reactive oxygen species and protects against cell death)8; KLF6 (a transcription factor that 
influences fibrogenesis)9; and ATGR1 (angiotensin type 1 receptor)10. In addition to these genetic factors and 
metabolic syndrome, hepatic iron also influences lipid metabolism and hepatic steatosis. Iron overload can cause 
oxidative stress and lipid peroxidation, and can, for example, increase the formation of intracellular lipid droplets 
in liver cells in vitro. Conversely, iron deficiency has been shown to increase lipogenesis in rat liver, resulting 
in triglyceride accumulation and steatosis11. Thus, NAFLD is a common and highly complex pathological state 
affected by many different interacting factors that can potentially influence its onset and development into more 
severe diseases.
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We previously found that targeted deletion of the Kcne2 gene causes iron deficiency anemia, and also hyper-
cholesterolemia12. KCNE2 is a potassium channel β subunit linked to cardiac arrhythmias and atherosclerosis13–15. 
The five-strong KCNE gene family comprises single transmembrane span proteins (KCNE subunits, also referred 
to as Mink-related peptides or MiRPs) that co-assemble with and alter the functional attributes of voltage-gated 
potassium (Kv) channel pore-forming (α ) subunits16. Like other KCNE subunits, KCNE2 is widely expressed in a 
variety of tissues, and can promiscuously associate with several different Kv α subunits17.
Aside from its roles in cardiac myocytes, where KCNE2 regulates hERG, Kv4.2, Kv1.5 and Kv2.1 depending 
on the species13,18–21, KCNE2 also co-assembles with the KCNQ1 α subunit22. This complex is important for 
various epithelial tissues, including the stomach, thyroid and choroid plexus18,19,23,24. Importantly, Kcne2─/─ mice 
exhibit achlorhydria, because KCNQ1-KCNE2 channels are required for normal function of the parietal cell H+/
K+-ATPase, and therefore gastric acid secretion24,25. Kcne2 deletion results in mis-trafficking of KCNQ1 channels 
to the basolateral side of parietal cells, where they cannot fulfil their normal function, and ultimately leads to gas-
tritis cystica profunda and gastric neoplasia26,27. Because the Kcne2-linked achlorhydria impairs iron uptake and 
causes iron deficiency anemia, a potential cause of abnormalities in hepatic lipid metabolism, here we investigated 
Kcne2-dependent hepatic lipid content and transcriptome remodeling, and discovered that Kcne2 deletion causes 
NAFLD.
Results and Discussion
Postnatal day 21 (P21) Kcne2─/─ pups exhibited lower bodyweight compared to wild-type (Kcne2+/+) counter-
parts (Fig. 1A), but had elevated serum triglycerides (Fig. 1B). Serum ALT and AST levels were also elevated in 
P21 Kcne2─/─ pups (Fig. 1C) whereas bilirubin was unchanged (Fig. 1D). These findings are consistent with early 
NAFLD, which was further explored using histology. Liver tissue from P21 Kcne2─/─ pups had a more vacuolated 
appearance than those from wild-type pups (Fig. 1E) and Kcne2 deletion caused marked accumulation of lipid in 
both P7 (Fig. 1F) and P21 (Fig. 1G, H) pup livers, confirming that Kcne2─/─ pups had early-onset NAFLD.
Microarray transcriptome analysis (Supplemental Spreadsheet 1) followed by regulator effect analysis 
(Ingenuity Pathway Analysis, Qiagen) of differentially expressed genes (DEGs) in livers of P21 Kcne2─/─ pups 
compared to Kcne2+/+ littermates identified the network with the highest consistency score as one including 
beta-oxidation of fatty acids, glucose concentration and hepatic steatosis, controlled by the transcriptional 
co-activator and regulator of genes important for energy metabolism, Peroxisome proliferator-activated recep-
tor gamma co-activator 1-α (PGC-1α , encoded by PPARGC1A) (Fig. 2A). The specific transcriptional changes 
observed within functional gene networks in the liver were highly consistent with remodeling in response to 
development of NAFLD, e.g., increased beta-oxidation of fatty acids in response to the lipid accumulation, and 
increased glucose-6 phosphatase catalytic subunit (G6PC) expression (knockout of glucose-6 phosphatase causes 
hepatic steatosis in mice28). Thus, the associated transcriptome changes were likely not causing the NAFLD but 
were the result of remodeling in response to it, indicating that the Kcne2─/─ liver was responding (albeit insuf-
ficiently) to abnormally high lipid accumulation. These changes occurred despite the lack of Kcne2 expression 
in Kcne2+/+ mouse liver (Fig. 2B), suggesting that Kcne2-dependent NAFLD arose via an initially extrahepatic 
defect.
Again employing an unbiased comparison of Kcne2─/─ versus Kcne2+/+ mouse liver transcriptomes from P21 
pups, Ingenuity pathway analysis software identified Inborn error of lipid metabolism as the primary disease/bio-
logical function gene set exhibiting differential expression arising from Kcne2 deletion (Fig. 2C). The gene within 
this set exhibiting the greatest magnitude change in hepatic expression was apolipoprotein B (ApoB), which was 
3.2-fold upregulated in livers from Kcne2─/─ versus Kcne2+/+ mice (n = 8 per genotype, P < 0.05). This is of par-
ticular interest because ApoB is the predominant apolipoprotein of low and intermediate density lipoproteins and 
chylomicrons, with one ApoB100 molecule per hepatic-derived lipoprotein (ApoB100 being the full-length pro-
tein product of the ApoB gene and the only form of the protein synthesized in the liver). Hepatic ApoB expression 
is therefore a useful index of hepatic lipoprotein concentration, and its increase in response to Kcne2 deletion is 
highly consistent with NAFLD. Furthermore, previous studies showed that the human ApoB/A1 ratio positively 
correlates (independent of other risk factors) with prevalence of NAFLD29. Our transcriptomic analysis indicates 
that the hepatic ApoB/A1 transcript ratio is increased 2.3-fold by Kcne2 deletion (Supplemental Spreadsheet 1), 
again consistent with a diagnosis of NAFLD in Kcne2─/─ mice.
Kcne2 deletion-linked achlorhydria24 causes iron-deficiency anemia12,30, which can predispose to dyslipidemia 
and NAFLD11. Although data vary depending on the animal model studied, iron deficiency in rats, for example, 
has been reported to increase hepatic lipogenesis, causing steatosis; this may occur via increased de novo lipogen-
esis from glucose31. Here, to investigate the possible role of iron deficiency in Kcne2 deletion-linked NAFLD, we 
initially utilized transcriptomic analysis in conjunction with iron supplementation. Non-treated P21 Kcne2─/─ liv-
ers exhibited extensive transcriptome remodeling indicative of NAFLD and anemia (Supplemental Spreadsheet 1). 
The 6 top-ranked DEG networks as identified by pathway analysis were: increased beta oxidation of fatty acids, 
elevated carbohydrates, hepatic steatosis, survival of erythroid progenitor cells and red blood cells, and prolif-
eration of embryonic stem cells (Fig. 3). Strikingly, supplementation with injectable iron (iron dextran) elim-
inated the differences in concerted gene expression caused by Kcne2 deletion that are associated with anemia 
(demonstrating that the iron supplementation we employed was effective in restoring iron levels and preventing 
anemia) and also the gene expression changes associated with NAFLD. Thus, only 5 of the 116 DEGs in the top 
6 DEG networks were still differentially expressed in Kcne2─/─ livers after iron treatment (Fig. 3; Supplemental 
Spreadsheet 2).
Consistent with the finding that iron supplementation prevented the transcriptome changes associated with 
NAFLD in Kcne2─/─ pups, iron supplementation also prevented excessive vacuolation in the liver and elimi-
nated Kcne2-dependent differences in hepatic lipid accumulation in the liver (Fig. 4A–C). A comparison of 
hepatic oil red O staining in iron-treated versus non-treated Kcne2─/─ pups indicated successful alleviation of 
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hepatic steatosis by iron supplementation (one-way ANOVA, p = 0.03). Thus, iron deficiency is a major factor in 
Kcne2-dependent, early-onset NAFLD. Note that the moderate increase in hepatic lipids of Kcne2+/+ pups treated 
with iron likely arose from iron overload which, as with iron deficiency, can also cause hepatic steatosis11.
To increase confidence that iron deficiency played the major role in Kcne2-dependent NAFLD, we exam-
ined other potential causes. Kcne2 deletion also causes cardiac dysfunction, which can lead to right-heart fail-
ure and associated liver fibrosis12,19,20. Although the livers studied here were from global Kcne2─/─ pups at P21, 
at which age they do not show signs of heart failure12,19,20, we next examined livers isolated from mice with a 
cardiac-specific Kcne2 deletion, to rule out a direct role for cardiac dysfunction in Kcne2-dependent NAFLD. 
Accordingly, only 15/116 DEGs in the top 6 DEG networks identified in global Kcne2─/─ mouse livers were also 
differentially expressed in cardiac-specific Kcne2─/─ mouse livers, strongly suggesting against a cardiac role in 
Kcne2─/─ NAFLD initiation (Fig. 3; Supplemental Spreadsheet 3).
Figure 1. Kcne2 deletion causes NAFLD. (A) Representative image (left) and mean body weight (right) of 3-week-
old male Kcne2+/+ and Kcne2─/─ mice (n = 8). Statistical analysis was by 2-tailed student’s t-test. (B) Mean serum 
triglyceride concentration for normal diet-fed 3-week-old male Kcne2+/+ and Kcne2─/─ mice (n = 3 per group). 
Statistical analysis was by 2-tailed student’s t-test. (C) Mean serum ALT and AST concentrations for normal diet-fed 
3-week-old Kcne2+/+ and Kcne2─/─ mice (n = 6–7 per group). Statistical analysis was by 2-tailed student’s t-test.  
(D) Mean serum total (t) and direct (d) bilirubin (Bil) concentration for normal diet-fed 3-week-old male Kcne2+/+ 
and Kcne2─/─ mice (n = 5–7 per group). Statistical analysis was by 2-tailed student’s t-test. (E) Representative images 
of hematoxylin and eosin-stained liver left lobe sections from 3-week-old Kcne2+/+ and Kcne2─/─ mice (n = 3). 
(F) Representative images of oil red O stained liver left lobe sections from 1-week-old Kcne2+/+ and Kcne2─/─ 
mice (n = 3). (G) Representative images of oil red O stained liver left lobe sections from 3-week-old Kcne2+/+ and 
Kcne2─/─ mice (n = 3). (H) Oil red O stain blinded scores for images as in panel G (n = 3). A score of 5 indicates 
strongest staining.
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Kcne2 deletion also results in hypothyroidism because KCNQ1-KCNE2 channels facilitate thyroid iodide 
uptake by the sodium iodide symporter19,32. Pups of Kcne2─/─ dams are hypothyroid regardless of their own gen-
otype because they rely on milk for iodide and/or thyroid hormones, whereas Kcne2─/─ mice bred from Kcne2+/─ 
dams do not exhibit signs of hypothyroidism until adulthood19. However, because hypothyroidism is a risk factor 
for NAFLD and even upper-normal levels of TSH associate with human NAFLD33, and because we previously 
observed findings suggestive of liver fibrosis in hypothyroid Kcne2─/─ mice19, here we nevertheless examined 
this possibility, by comparing livers of P21 Kcne2─/─ pups bred from Kcne2+/─ versus Kcne2─/─ dams. Only 14 
DEGs identified when comparing livers of Kcne2─/─ pups versus those of Kcne2+/+ pups (Fig. 3) were also iden-
tified as being differentially expressed in Kcne2─/─ pups from Kcne2─/─ dams versus those from Kcne2+/─ dams 
(Fig. 5A), and none of these were within the 6 identified anemia/NAFLD networks (Fig. 3). Furthermore, net-
work analysis of DEGs in livers of Kcne2─/─ pups from Kcne2─/─ dams versus those from Kcne2+/─ dams revealed 
less-populated networks, spanning a range of physiological processes and not biased toward NAFLD (Fig. 5B). 
Kcne2-dependent NAFLD in pups from heterozygous dams, as we used in the current study, is therefore not ini-
tiated by hypothyroidism.
Figure 2. Kcne2-dependent changes in interacting hepatic gene networks. (A) The liver DEG interacting 
networks (after microarray transcriptome analysis of liver tissue from global Kcne2─/─ versus Kcne2+/+ mice, 
n = 8 mice per group) with the highest consistency score included beta-oxidation of fatty acids, glucose 
concentration and hepatic steatosis, with predicted hierarchical control by PPARGC1A (IPA software, 
Qiagen). (B) Real-time qPCR does not detect Kcne2 transcript expression in Kcne2+/+ mouse liver. Kcne2+/+ 
stomach tissue was used as a positive control, Kcne2─/─ tissue as a negative control; n = 3–4 mice per group, 
each quantified in triplicate. (C) The first-ranked disease process/biological function gene set altered by Kcne2 
deletion was Inborn error of lipid metabolism, identified by Ingenuity pathway analysis of hepatic transcriptome 
changes quantified by microarray analysis as in panel A (P = 5.1 × 10−7, n = 8 per genotype).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:23118 | DOI: 10.1038/srep23118
Taken together, our data support a primary role for iron deficiency, but not hypothyroidism or heart failure, 
in initiating Kcne2-dependent NAFLD. Similarly, iron deficiency can predispose to dyslipidemia and NAFLD 
in human populations11, both of which are risk factors for atherosclerosis34, as are certain human KCNE2 
polymorphisms3.
In addition, we found that serum C-reactive protein (CRP), an atherosclerotic biomarker released by 
the liver in response to inflammation, was elevated in Kcne2─/─ mice - most prominently in western diet-fed 
females (Fig. 6A). This correlates with recently-discovered atherosclerotic predisposition in Kcne2─/─ mice15 and 
is also consistent with presence of NAFLD, although elevated CRP is not a specific biomarker for NAFLD35. 
Achlorhydria also causes hyperhomocysteinemia, another atherosclerosis risk factor36; accordingly, Kcne2 dele-
tion increased serum homocysteine (Fig. 6B), providing another possible mechanistic link between achlorhy-
dria (impairing vitamin B absorption, causing hyperhomocysteinemia) and atherosclerosis in Kcne2─/─ mice. 
Importantly, hyperhomocysteinemia has also been positively correlated with NAFLD in human populations, and 
in mouse models has been suggested to lead to hepatic steatosis via abnormal lipid metabolism37. Thus, although 
iron supplementation prevents hepatic steatosis in Kcne2─/─ mice, it is possible that their hyperhomocysteinemia 
also contributes or predisposes to NAFLD in the setting of anemia (perhaps in a double-hit scenario).
In conclusion, our data support a substantial role for Kcne2-linked iron deficiency in the development of 
NAFLD in mice. Future studies will determine if this novel genetic link is recapitulated in humans, and investigate 
potential interactions between KCNE2-associated atherosclerosis, dyslipidemia, NAFLD, and diet-dependent 
cardiac arrhythmogenesis and sudden death15.
Figure 3. Iron supplementation prevents NAFLD-associated transcriptome changes in Kcne2─/─ mouse 
livers. (A) Schema showing genotypes, treatment and analyses for Kcne2-dependent hepatic transcriptome 
analysis. (B) DEG networks (IPA software, Qiagen) when comparing liver tissue harvested from 3-week-
old global-knockout Kcne2─/─ versus Kcne2+/+ pups (organized by cellular compartment), after microarray 
transcriptome analysis (n = 8 mice per group). Red, upregulated; green, downregulated, in Kcne2─/─ versus 
Kcne2+/+ livers. Venn analysis revealed that iron supplementation from birth eliminated all but 5 transcript 
changes (subset: iron treated) and that cardiac-specific Kcne2 deletion resulted in only 15 liver DEGs (subset: 
cardiac-specific Kcne2─/─) common to those altered by global Kcne2 deletion.
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Methods
Generation of mice and study protocol. The Kcne2─/─ mouse line was generated as we previously 
described24, and mice used in this study were bred by crossing Kcne2+/─ mice which had been backcrossed > 10 
times into the C57BL/6 strain. After being genotyped and weaned at 3 weeks of age, mice pups were assigned 
to, and maintained on, either a control diet (2020X, Harlan, 16% kcal from fat; 19.1% protein, 2.7% crude fiber, 
12.3% neutral detergent fiber and 0% cholesterol) or western diet (TD.88137, Harlan, 42% kcal from fat, > 60% of 
which is saturated; 34% sucrose; 0.2% cholesterol). Cardiac-specific Kcne2─/─ mice, used as a control in the liver 
analyses, were generated using a mouse line expressing Cre-recombinase under the control of the α MHC (alpha 
myosin heavy chain) promoter; a full phenotypic description of this mouse line will appear in a separate, future 
study. Mouse tissue and blood serum were then collected for further analysis or stored at − 80 °C.
Whole-transcript Microarray analysis. Mice were euthanized, and then tissue was harvested and pre-
served in RNAlater (Invitrogen) until use. Total RNA was collected from the liver, reverse-transcribed into cDNA 
and analyzed by “whole-transcript transcriptomics” using the GeneAtlas microarray system (Affymetrix) and 
manufacturer’s protocols. MoGene 1.1 ST array strips (Affymetrix) were used to hybridize to newly synthesized 
sscDNA. Each array comprised 770,317 distinct 25-mer probes to probe an estimated 28,853 transcripts, with 
a median 27 probes per gene. Gene expression changes associated with Kcne2 deletion were analyzed using 
Ingenuity Pathway Analysis (Qiagen) to identify biological networks, pathways, processes and diseases that were 
most highly represented in the differentially expressed gene (DEGs) identified. Expression changes of ≥ 1.5 fold 
and p < 0.05 were included in the analysis.
RNA isolation and Real-Time qPCR. Mice were euthanized by CO2 asphyxiation. Gastric fundus tissue 
was harvested and washed with PBS; livers were harvested, washed and perfused through left ventricle with PBS 
+ heparin, then all tissue either processed or stored at − 80 °C until use. RNA was extracted using 1 ml of Trizol 
(Invitrogen) per 100 mg of tissue and purified using the RNeasy Mini Kit (Qiagen) according to the manufactur-
er’s protocol. RNA samples with A260/A280 absorbance ratios between 2.00–2.20 were used for further synthesis. 
500 ng to 1 μg of RNA was used for cDNA synthesis (Qiagen’s Quantitect Reverse Transcriptase) and stored at 
− 20 °C until use. Primer pairs for target gene Kcne2 (NCBI Gene ID: 246133) and Gapdh (NCBI Gene ID: 14433) 
produced amplicons of 175 bp and 123 bp respectively. The qPCR primer sequences were as follows:
Kcne2, forward 5′ -CACATTAGCCAATTTGACCCAG-3′ , and reverse 5′ -GAACATGCCGATCATCACCAT-3′ ; 
Gapdh, forward 5′ -AGGTCGGTGTGAACGGATTTG-3′ ; and reverse 5′ -TGTAGACCATGTAGTTGAGGTCA-3. 
Primers (0.05 μm synthesis scale, HPLC purified) were acquired from Sigma. Real-time qPCR analysis was per-
formed using the CFX Connect System, iTaq Universal SYBR Green Supermix (BioRad) and 96-well clear plates. 
Thermocycling parameters were set according to manufacturer’s protocol for iTaq. Samples were run in triplicate 
as a quality control measure and triplicates with a standard deviation of 0.6 or higher were repeated. Melting 
curves were assessed for verification of a single product. ∆ ∆ Cq values were normalized to those obtained for the 
Kcne2+/+ stomach tissue.
Iron supplementation study. To determine the potential beneficial effects of alleviating iron-deficiency 
anemia, post-partum dams were first intraperitoneally (IP) injected with iron dextran (25 mg/kg) or vehicle con-
trol (saline) on the day their pups were born. Mouse pups were then injected with iron dextran (12.5 mg/kg) or 
Figure 4. Iron supplementation prevents Kcne2 deletion-associated NAFLD. (A) Representative images of 
hematoxylin and eosin-stained liver left-lobe sections from iron dextran-treated P21 global Kcne2─/─ versus 
Kcne2+/+ mice (n = 9–16). (B) Representative images of oil-red-O-stained liver left-lobe sections from iron 
dextran-treated P21 global Kcne2─/─ versus Kcne2+/+ mice (n = 9–16). (C) Oil red O stain blinded scores for 
images as in panel B (n = 9–16). A score of 5 indicates strongest staining.
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Figure 5. NAFLD in P21 Kcne2─/─ pups is not altered by maternal genotype. (A) Left, schema showing 
genotypes, treatment and analyses for effects of maternal genotype on Kcne2-dependent hepatic steatosis study. 
Right, the 14 DEGs identified when comparing livers of Kcne2─/─ pups versus those of Kcne2+/+ pups (Fig. 3) 
that were also differentially expressed in Kcne2─/─ pups from Kcne2─/─ dams versus those from Kcne2+/─ dams; 
none of these were within the 6 identified anemia/NAFLD networks from Fig. 3. (B) DEG networks (IPA 
software, Qiagen) when comparing liver tissue harvested from 3-week-old global-knockout Kcne2─/─ pups 
from Kcne2─/─ dams versus Kcne2─/─ pups from Kcne2+/─ dams (organized by cellular compartment), after 
microarray transcriptome analysis (n = 8 mice per group). Red, upregulated; green, downregulated, in Kcne2─/─ 
versus Kcne2+/+ livers.
Figure 6. Kcne2 deletion causes elevated serum CRP and homocysteine. (A) Mean serum C-reactive protein 
(CRP) concentration for 6–9 month-old Kcne2+/+ and Kcne2─/─ mice. n = 7–10, male control diet; n = 8, 
male western diet; n = 4–7, female control diet; n = 8, female western diet; P values are for 2-tailed, unpaired 
t-tests for inter-genotype comparisons within equivalent sex and diet groups. (B) Mean serum homocysteine 
concentration for 6–9-month-old Kcne2+/+ and Kcne2─/─ mice. n = 4, male control diet; 4, male western diet; 
3–4, female control diet; 3–5, female western diet; p values are for 2-tailed, unpaired t-tests for inter-genotype 
comparisons within equivalent sex and diet groups.
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vehicle control (saline) at P7 and P14. Whole livers and blood serum were then harvested for analysis at P21. Liver 
section oil red O staining was performed by UC Irvine pathology core facility, and then the extent of staining was 
quantified by a scorer blinded to genotype, treatment, and hypothesis. Representative images were then chosen 
based on the mean score for each group.
Blood analysis. To quantify triglycerides, serum was collected after euthanasia from 3-week-old male mouse 
pups and then analyzed using a glycerol oxidation-based colorimetric assay (Abcam, United Kingdom). CRP and 
homocysteine were quantified in serum collected after sacrificing 6–9-month-old mice, using ELISA (R&D sys-
tems, MN) and the Mouse Homocysteine Assay kit (quantifying hydrogen sulfide resulting from degradation of 
homocysteine by homocysteinase) (Crystal Chem, IL, USA), respectively. Alanine transaminase (ALT), aspartate 
transaminase (AST), and total and direct (conjugated) bilirubin concentrations in P21 mouse serum were quan-
tified using a Mindray BS-120 Chemistry Analyzer (Mindray Medical Corporation, Shenzhen, China).
Statistical analysis. Statistical analyses (student’s t-test or ANOVA, as indicated in the figure legends) were 
performed assuming statistical significance with p values < 0.05.
Study approval. All mice were housed in pathogen-free facilities and the study was approved by the Animal 
Care and Use Committee at University of California, Irvine. Studies were performed during the light cycle and 
were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health.
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